Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Survey of burnout in U.S. Epilepsy physicians.

Epilepsy & behavior : E&B·2026
Same author

M-ECG: extracting heart signals with a novel computational analysis of magnetoencephalography data.

Frontiers in neuroimaging·2026
Same author

The Cost-Effectiveness of CDK4/6 Inhibitors in Treating HR+/HER2- Metastatic Breast Cancer Patients in the USA: When Non-medication Expenses are Considered.

Clinical drug investigation·2025
Same author

Positive anxiety or depression screen despite ongoing antidepressant prescription in people with epilepsy: A large cross-sectional analysis.

Epilepsy & behavior reports·2022
Same author

Racial differences in the association of body mass index and ovarian cancer risk in the OCWAA Consortium.

British journal of cancer·2022
Same author

Are Wellness Visits a Possible and Effective Cure for the Increasing Cancer Burden in Poland? Example of Women's Preventive Services in the U.S.

Cancers·2022

Related Experiment Video

Updated: Jul 15, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Analysis of NAMCS data for multiple sclerosis, 1998-2004.

Jagannadha R Avasarala1, Cormac A O'Donovan, Steve E Roach

  • 1Kansas Neurological Consultants, Wichita, KS 67218, USA. javasarala@yahoo.com

BMC Medicine
|April 7, 2007
PubMed
Summary

This study analyzed immunomodulatory agent (IMA) prescribing patterns for multiple sclerosis (MS) patients in US outpatient settings from 1998-2004. Findings indicate a need for improved IMA utilization strategies in MS management.

More Related Videos

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Related Experiment Videos

Last Updated: Jul 15, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Area of Science:

  • Neurology
  • Pharmacology
  • Public Health

Background:

  • Prescribing patterns of immunomodulatory agents (IMAs) for multiple sclerosis (MS) in US outpatient settings remain understudied.
  • This research addresses the knowledge gap by analyzing retrospective data.

Purpose of the Study:

  • To investigate the prescribing patterns of IMAs in US outpatient settings for MS patients.
  • To analyze patient demographics and treatment trends during the study period.

Main Methods:

  • Retrospective analysis of National Ambulatory Medical Care Survey (NAMCS) data from 1998 to 2004.
  • Examined MS patient visits by specialist type, patient demographics, and IMA treatment status.

Main Results:

  • An estimated 6.7 million MS outpatient visits occurred between 1998-2004, with neurologists seeing the majority.
  • While overall IMA usage showed no significant trend, interferon-1a use declined, and interferon-1b and glatiramer acetate use increased.
  • A substantial proportion of MS patients, particularly those seen by non-neurologists, were not on IMA treatment.

Conclusions:

  • Current strategies for IMA use in outpatient MS management require enhancement.
  • Further research and interventions are necessary to optimize IMA prescribing and patient outcomes.